← Back to Search

Behavioral Intervention

Communication Tool Adaptation for HIV Prevention (PrEP Trial)

N/A
Waitlist Available
Led By Mirjam-Colette Kempf, PhD, MPH
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cisgender African American HIV-uninfected women aged 18 years or older who speak English and report HIV risk and/or recent PrEP use
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months and 12 months
Awards & highlights

PrEP Trial Summary

This trial will adapt and test a communication tool to increase PrEP uptake among at-risk African American women in rural areas of the southern US.

Who is the study for?
This trial is for African American, cisgender women over the age of 18 who speak English and are at risk for HIV but not infected. They should recognize their HIV risk or have used PrEP recently. Healthcare providers such as physicians, nurses, or social workers cannot participate.Check my eligibility
What is being tested?
The study aims to increase PrEP uptake among at-risk African American women in rural Alabama by adapting a communication tool from the CDC's PrEP toolkit. This tool will help with recognizing HIV risk and interest in starting PrEP through referrals to local clinics.See study design
What are the potential side effects?
Since this trial focuses on cultural adaptation of a communication tool rather than a medical intervention, traditional side effects associated with medications are not applicable here.

PrEP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am an African American woman over 18, speak English, at risk for HIV or have used PrEP recently.

PrEP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intervention acceptability
Intervention feasibility changes
PrEP uptake changes
Secondary outcome measures
Biological measures of HIV, STIs and pregnancy
Clinic visit adherence changes
PrEP adherence

PrEP Trial Design

1Treatment groups
Experimental Treatment
Group I: Cultural adaptation of a patient-provider communication toolExperimental Treatment1 Intervention
Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,798 Previous Clinical Trials
2,660,793 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,594 Previous Clinical Trials
2,282,970 Total Patients Enrolled
Massachusetts General HospitalOTHER
2,943 Previous Clinical Trials
13,200,824 Total Patients Enrolled

Media Library

Cultural adaptation of a patient-provider communication tool (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04373551 — N/A
HIV/AIDS Research Study Groups: Cultural adaptation of a patient-provider communication tool
HIV/AIDS Clinical Trial 2023: Cultural adaptation of a patient-provider communication tool Highlights & Side Effects. Trial Name: NCT04373551 — N/A
Cultural adaptation of a patient-provider communication tool (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04373551 — N/A
~29 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top